EUR 76.5
(0.0%)
Year | Operating Income | Operating Income Growth |
---|---|---|
2023 | 74.26 Million EUR | -43.39% |
2022 | 79.31 Million EUR | 2.64% |
2021 | 77.27 Million EUR | 47.21% |
2020 | 52.49 Million EUR | 14.16% |
2019 | 45.98 Million EUR | -4.75% |
2018 | 48.27 Million EUR | 5.76% |
2017 | 45.64 Million EUR | 8.49% |
2016 | 42.07 Million EUR | 8.58% |
2015 | 38.74 Million EUR | 10.22% |
2014 | 35.15 Million EUR | 4.82% |
2013 | 33.53 Million EUR | 6.66% |
2012 | 31.44 Million EUR | -1.18% |
2011 | 31.82 Million EUR | -1.03% |
2010 | 32.15 Million EUR | 11.15% |
2009 | 28.92 Million EUR | 4.85% |
2008 | 27.58 Million EUR | -1.75% |
2007 | 28.07 Million EUR | 12.98% |
2006 | 24.85 Million EUR | 31.94% |
2005 | 18.83 Million EUR | 0.0% |
Year | Operating Income | Operating Income Growth |
---|---|---|
2024 Q2 | 33.03 Million EUR | 0.0% |
2023 Q2 | 35.91 Million EUR | 0.0% |
2023 Q4 | 20.1 Million EUR | 0.0% |
2023 FY | 44.9 Million EUR | -43.39% |
2022 Q4 | 37.46 Million EUR | 0.0% |
2022 FY | 79.31 Million EUR | 2.64% |
2022 Q2 | 41.84 Million EUR | 0.0% |
2021 FY | 77.27 Million EUR | 47.21% |
2021 Q2 | 48.7 Million EUR | 0.0% |
2021 Q4 | 28.56 Million EUR | 0.0% |
2020 Q2 | 22.41 Million EUR | 0.0% |
2020 Q4 | 28.68 Million EUR | 0.0% |
2020 FY | 52.49 Million EUR | 14.16% |
2019 Q2 | 17.85 Million EUR | 0.0% |
2019 FY | 45.98 Million EUR | -4.75% |
2019 Q4 | 23.84 Million EUR | 0.0% |
2018 Q2 | 17.78 Million EUR | 0.0% |
2018 FY | 48.27 Million EUR | 5.76% |
2018 Q4 | 30.48 Million EUR | 0.0% |
2017 Q4 | 25.07 Million EUR | 0.0% |
2017 Q2 | 20.57 Million EUR | 0.0% |
2017 FY | 45.64 Million EUR | 8.49% |
2016 Q4 | 22.15 Million EUR | 0.0% |
2016 Q2 | 19.91 Million EUR | 0.0% |
2016 FY | 42.07 Million EUR | 8.58% |
2015 FY | 38.74 Million EUR | 10.22% |
2015 Q4 | 22.72 Million EUR | 0.0% |
2015 Q2 | 16.02 Million EUR | 0.0% |
2014 Q4 | 21.11 Million EUR | 0.0% |
2014 Q2 | 14.03 Million EUR | 0.0% |
2014 FY | 35.15 Million EUR | 4.82% |
2013 FY | 33.53 Million EUR | 6.66% |
2013 Q2 | 13.97 Million EUR | 0.0% |
2013 Q4 | 19.56 Million EUR | 0.0% |
2012 FY | 31.44 Million EUR | -1.18% |
2012 Q2 | 7.84 Million EUR | 0.0% |
2012 Q4 | 8.22 Million EUR | 4.79% |
2012 Q3 | 7.84 Million EUR | 0.0% |
2012 Q1 | 7.84 Million EUR | 0.0% |
2011 Q2 | 8.01 Million EUR | 0.0% |
2011 Q1 | 8.01 Million EUR | 0.0% |
2011 Q3 | 8.01 Million EUR | 0.0% |
2011 Q4 | 7.84 Million EUR | -2.08% |
2011 FY | 31.82 Million EUR | -1.03% |
2010 Q2 | 8.26 Million EUR | 0.0% |
2010 Q3 | 8.26 Million EUR | 0.0% |
2010 Q4 | 8.01 Million EUR | -3.1% |
2010 FY | 32.15 Million EUR | 11.15% |
2010 Q1 | 8.26 Million EUR | 0.0% |
2009 FY | 28.92 Million EUR | 4.85% |
2009 Q1 | 7.23 Million EUR | 0.0% |
2009 Q4 | 8.26 Million EUR | 14.35% |
2009 Q3 | 7.23 Million EUR | 0.0% |
2009 Q2 | 7.23 Million EUR | 0.0% |
2008 Q1 | 6.84 Million EUR | 0.0% |
2008 FY | 27.58 Million EUR | -1.75% |
2008 Q4 | 7.23 Million EUR | 5.6% |
2008 Q3 | 6.84 Million EUR | 0.0% |
2008 Q2 | 6.84 Million EUR | 0.0% |
2007 Q2 | 5.89 Million EUR | 0.0% |
2007 Q1 | 5.89 Million EUR | 0.0% |
2007 FY | 28.07 Million EUR | 12.98% |
2007 Q4 | 6.84 Million EUR | 16.2% |
2007 Q3 | 5.89 Million EUR | 0.0% |
2006 Q2 | 5.52 Million EUR | 0.0% |
2006 FY | 24.85 Million EUR | 31.94% |
2006 Q1 | 5.52 Million EUR | 0.0% |
2006 Q3 | 5.52 Million EUR | 0.0% |
2006 Q4 | 5.89 Million EUR | 6.67% |
2005 Q4 | 5.52 Million EUR | 18.98% |
2005 FY | 18.83 Million EUR | 0.0% |
2005 Q1 | 4.64 Million EUR | 0.0% |
2005 Q2 | 4.64 Million EUR | 0.0% |
2005 Q3 | 4.64 Million EUR | 0.0% |
2004 Q4 | 4.64 Million EUR | 0.0% |
Name | Operating Income | Operating Income Difference |
---|---|---|
Boiron SA | 42.29 Million EUR | -75.607% |
Laboratorios Farmaceuticos Rovi, S.A. | 220.25 Million EUR | 66.283% |
Valneva SE | -82.08 Million EUR | 190.47% |
AB Science S.A. | -13.42 Million EUR | 653.012% |
Nanobiotix S.A. | -26.77 Million EUR | 377.322% |
PHAXIAM Therapeutics S.A. | -23.66 Million EUR | 413.88% |
Vivoryon Therapeutics N.V. | -28.83 Million EUR | 357.53% |
BioSenic S.A. | -7.04 Million EUR | 1154.886% |
ABIVAX Société Anonyme | -127.37 Million EUR | 158.303% |
Formycon AG | -369 Thousand EUR | 20225.745% |